Background Mucormycosis is a serious fungal infection associated with uncontrolled diabetes and immunocompromised patients. This angioinvasive infection emerged as a post‐covid complication worldwide especially in developing countries. Due to the common socio‐demographic status of South Asian countries, we expected a surge in mucormycosis cases in Pakistan. This study aims to observe the frequency and survival of Covid associated mucormycosis patients at tertiary care hospitals in Pakistan during the third wave of Covid‐19 in 2021. Materials and Methods In this retrospective study, we collected the data of clinically and histopathologically confirmed cases of rhino‐occipito‐cerebral mucormycosis from three tertiary care hospitals of Lahore. These cases were analysed for history of Covid‐19 and other associated comorbidities using SPSS28. History of steroid medication was also taken. Data were retrieved from May to July 2021 after the approval from the ethical review board. Results Out of the total 43 reported patients of mucormycosis in the set time frame only 22 cases had a history of Covid‐19. The mean age was 50 ± 13.27 years with slight male predilection (60%). Diabetes mellitus was the most common comorbidity (88.4%) and all the patients with covid associated mucormycosis (CAM) had taken corticosteroid regimen for covid management ( p < 0.0001). The survival of the patient was not significantly different between CAM and non‐CAM patients of Mucormycosis ( p = 0.747). Conclusion Covid‐19 and mucormycosis make a lethal duo against the weakened health system of Pakistan. This problem can be prevented by avoiding nonjudicial use of corticosteroids and proper diabetes control program following Covid‐19 infection. Furthermore, large‐scale epidemiological studies should be carried out to evaluate the true burden of Mucormycosis in the population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.